Product
Vapendavir
2 clinical trials
35 indications
Indication
COPD ExacerbationIndication
RhinovirusIndication
Virus DiseasesIndication
Viral InfectionIndication
RNAIndication
EnterovirusIndication
Enterovirus InfectionsIndication
Human Rhinovirus InfectionIndication
Respiratory ComplicationIndication
respiratory diseaseIndication
Respiratory Tract InfectionsIndication
Respiratory Tract DiseasesIndication
Respiratory viral infectionIndication
Upper Respiratory Tract InfectionIndication
Upper Respiratory Tract InfectionsIndication
Upper Respiratory InfectionIndication
Upper Respiratory DisorderIndication
AcuteIndication
Viral Upper Respiratory InfectionIndication
InfectionsIndication
RespiratoryIndication
Chronic obstructive pulmonary diseaseIndication
viral infectionIndication
Chronic Obstructive Pulmonary DiseaseIndication
Lower Respiratory DiseaseIndication
Lower Respiratory DisorderIndication
Lower Respiratory Tract InfectionsIndication
Pulmonary DiseaseIndication
Chronic ObstructiveIndication
Chronic Respiratory DiseaseIndication
Lung DiseasesIndication
Chronic Lung DiseaseIndication
Chronic Lower Respiratory DiseasesIndication
HealthyClinical trial
A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus ChallengeStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1 Study to Confirm the Single- and Multiple-dose Pharmacokinetics and to Evaluate Food Effect of Vapendavir in Healthy Participants and Participants With COPDStatus: , Estimated PCD: 2023-08-01